Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Citius Oncology, Inc. (CTOR) had Return on Tangible Equity of -16.57% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-5.37M |
|
-- |
|
-- |
|
$4.95M |
|
$-4.95M |
|
$-0.16M |
|
$-5.11M |
|
$-5.11M |
|
$-5.37M |
|
$-5.37M |
|
$-5.37M |
|
$-5.37M |
|
$-4.95M |
|
$-4.95M |
|
71.55M |
|
71.55M |
|
$-0.08 |
|
$-0.08 |
|
| Balance Sheet Financials | |
$18.31M |
|
-- |
|
$73.40M |
|
$91.71M |
|
$52.99M |
|
$3.80M |
|
$6.32M |
|
$59.31M |
|
$32.40M |
|
$32.40M |
|
$32.40M |
|
71.55M |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
$0.00M |
|
$0.00M |
|
-- |
|
$6.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.35 |
|
-- |
|
-- |
|
0.10 |
|
0.35 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-16.57% |
|
|
Return on Tangible Equity |
-16.57% |
-5.86% |
|
-14.83% |
|
$0.45 |
|
-- |
|
-- |
|